TY  - JOUR
AU  - Guida, Florence
AU  - Sun, Nan
AU  - Bantis, Leonidas E
AU  - Muller, David C
AU  - Li, Peng
AU  - Taguchi, Ayumu
AU  - Dhillon, Dilsher
AU  - Kundnani, Deepali L
AU  - Patel, Nikul J
AU  - Yan, Qingxiang
AU  - Byrnes, Graham
AU  - Moons, Karel G M
AU  - Tjønneland, Anne
AU  - Panico, Salvatore
AU  - Agnoli, Claudia
AU  - Vineis, Paolo
AU  - Palli, Domenico
AU  - Bueno-de-Mesquita, Bas
AU  - Peeters, Petra H
AU  - Agudo, Antonio
AU  - Huerta, Jose M
AU  - Dorronsoro, Miren
AU  - Barranco, Miguel Rodriguez
AU  - Ardanaz, Eva
AU  - Travis, Ruth C
AU  - Byrne, Karl Smith
AU  - Boeing, Heiner
AU  - Steffen, Annika
AU  - Kaaks, Rudolf
AU  - Hüsing, Anika
AU  - Trichopoulou, Antonia
AU  - Lagiou, Pagona
AU  - La Vecchia, Carlo
AU  - Severi, Gianluca
AU  - Boutron-Ruault, Marie-Christine
AU  - Sandanger, Torkjel M
AU  - Vainio, Elisabete Weiderpass
AU  - Nøst, Therese H
AU  - Tsilidis, Kostas
AU  - Riboli, Elio
AU  - Grankvist, Kjell
AU  - Johansson, Mikael
AU  - Goodman, Gary E
AU  - Feng, Ziding
AU  - Brennan, Paul
AU  - Johansson, Mattias
AU  - Hanash, Samir M
TI  - Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.
JO  - JAMA oncology
VL  - N.N.
SN  - 2374-2437
CY  - Chicago, Ill.
PB  - American Medical Association
M1  - DKFZ-2018-01164
SP  - e182078 
PY  - 2018
AB  - There is an urgent need to improve lung cancer risk assessment because current screening criteria miss a large proportion of cases.To investigate whether a lung cancer risk prediction model based on a panel of selected circulating protein biomarkers can outperform a traditional risk prediction model and current US screening criteria.Prediagnostic samples from 108 ever-smoking patients with lung cancer diagnosed within 1 year after blood collection and samples from 216 smoking-matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were used to develop a biomarker risk score based on 4 proteins (cancer antigen 125 [CA125], carcinoembryonic antigen [CEA], cytokeratin-19 fragment [CYFRA 21-1], and the precursor form of surfactant protein B [Pro-SFTPB]). The biomarker score was subsequently validated blindly using absolute risk estimates among 63 ever-smoking patients with lung cancer diagnosed within 1 year after blood collection and 90 matched controls from 2 large European population-based cohorts, the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Northern Sweden Health and Disease Study (NSHDS).Model validity in discriminating between future lung cancer cases and controls. Discrimination estimates were weighted to reflect the background populations of EPIC and NSHDS validation studies (area under the receiver-operating characteristics curve [AUC], sensitivity, and specificity).In the validation study of 63 ever-smoking patients with lung cancer and 90 matched controls (mean [SD] age, 57.7 [8.7] years; 68.6
LB  - PUB:(DE-HGF)16
C6  - pmid:30003238
DO  - DOI:10.1001/jamaoncol.2018.2078
UR  - https://inrepo02.dkfz.de/record/136726
ER  -